Soft matter DNA nanoparticles hybridized with CpG motifs and peptide nucleic acids enable immunological treatment of cancer

J Control Release. 2019 Dec 10:315:76-84. doi: 10.1016/j.jconrel.2019.09.013. Epub 2019 Oct 19.

Abstract

Nucleic acids have been used as building blocks to assemble nanostructures by their sequence specific self-recognition properties, and resulting DNA architectures were applied as potential multifunctional drug carriers. Here, we report an amphiphilic lipid-DNA aggregate hybridized with pharmaceutically active DNA and peptide segments for cancer immunotherapy. The facile formulation of the CpG sequence and antigen peptide-bearing peptide nucleic acid representing immune-adjuvant and antigen, respectively, enabled the highly efficacious induction of antigen-specific immune activation. This immunotherapeutic formulation was evaluated in terms of multiple types of tumor growth and metastasis in vivo.

Keywords: Adjuvants; Anti-metastasis; Antigens; Cancer vaccines; Lipid-DNAs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Animals
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology
  • CpG Islands / immunology
  • DNA / administration & dosage*
  • DNA / immunology
  • Drug Carriers / chemistry
  • Immunotherapy / methods*
  • Lipids / chemistry
  • Melanoma, Experimental / immunology
  • Melanoma, Experimental / therapy
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Nanoparticles*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Peptide Nucleic Acids / administration & dosage
  • Peptide Nucleic Acids / immunology

Substances

  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Drug Carriers
  • Lipids
  • Peptide Nucleic Acids
  • DNA